Pfizer wins a $10 billion deal for weight-loss drugmaker Metsera, ending its bidding war with Danish rival Novo Nordisk.

Danish drugmaker Novo Nordisk announced a partnership with Emcure Pharma on Monday to launch its Poviztra, semaglutide injection 2.4 mg, in India. Poviztra is the second brand of its weight loss drug ...

COPENHAGEN (Reuters) -Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 billion ...

Pfizer Inc. chief executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...

Novo Nordisk (NYSE:NVO) climbs about 2% on early Monday after it says it will not raise its offer for Metsera (NASDAQ:MTSR), ...

Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.

A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and ...

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.